Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
28 results
- D3.134 - Evaluation of the level of asthma control in the pulmonology-phtisiology department of the Ignace Deen University Hospital
D3.133 - Association between Asthma and Risk of Respiratory Syncytial Virus-Acute Respiratory Infection in Adults 50 Years or Older Before and After the Covid 19-Pandemic in a Midwest Region of the U.S
D3.135 - Nasal and respiratory symptoms, functional features, and sensitization to platinum salts in platinum catalysts manufacturing workers
D3.136 - Worse asthma control in patients with asthma and respiratory allergies in the CAPTURE study: Rationale for developing the RespiratoryAllergyOptimiser
D3.137 - Effectiveness of Dupilumab in improving Quality of Life in patients with "steroid-resistant" asthma and severe atopic dermatitis
D3.138 - Asthma remission in EGPA patients: applicability and concordance of the main international guidelines
D3.139 - Asthma Comorbidities - do they add more cost, A 3-year follow-up study in Réunion Island
D3.140 - Xiaoqinglong Decoction Combined with Yupingfeng Powder Alleviates Allergic Rhinitis Complicated with Asthma by Inhibiting B Lymphocyte Activation via JAK2/STAT1/MHC-II signaling pathway
D3.142 - Differential Impact of Heat-not-Burn Tobacco Products and Conventional Cigarettes on Pulmonary Cells and Immune Response
D3.143 - Seasonal Patterns of Airborne Pollen in Ecuador: Influence of Wet and Dry Seasons on Allergenic Taxa Concentrations
D3.144 - Geographic Disparities in Air Pollution and Th2-Mediated Airway Inflammation in Mexico City: The Role of Industrial and Traffic Emissions
D3.146 - Impact of Switching from Omalizumab to Dupilumab in Severe Asthma Patients: A Retrospective Evaluation of Efficacy and Inflammatory Biomarkers
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
D3.416 - Hereditary Alpha-Tryptasemia: A Case Series
D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download